#D-dimer Testing trends | Explore Tumblr Posts and Blogs

mcfarlandsaunders53 · 2 months

Text

Sonography Shear Trend Elastography to gauge Muscle Hardware Attributes inside Somatic Disorder: A new Practicality Review.

Bottom line The region involving the lateral incisor actual as well as the canine incisor root in aircraft 4, Some, and eight millimeter through the alveolar ridge crest can be used as risk-free internet sites pertaining to implantation, even though 7 mm below the alveolar ridge crest could be the best implantation website. An ideal implantation internet site may be 8 mm under the alveolar ridge top between your lateral incisor main along with the doggy incisor root. Prior studies declare that coronavirus illness 2019 (COVID-19) can be a endemic disease including a number of systems, and might trigger autonomic malfunction. To guage autonomic function as well as bond the actual studies to the severeness and results in COVID-19 patients. Many of us included sequential individuals with COVID-19 admitted towards the Twenty first COVID-19 Office in the far east university involving Renmin Hospital associated with Wuhan University or college from January Six to 03 Seven, 2020. Clinical data ended up gathered. Heartbeat variability (HRV), N-terminal pro-B-type natriuretic peptide (NT-proBNP), D-dimer, and also lymphocytes along with subsets number ended up examined from 2 period items nucleic-acid test bad and the good. Subconscious signs and symptoms were considered after discharge. < Zero.001), standard change from the averages of NN times (SDANN) ( < 0.001), as well as a greater rate of low- to be able to high-frequency strength (LF/HF) ( Equates to 2.016). Straight line connections have been demonstrated among SDNN, SDANN, LF/HF, and also lab search engine spiders ( < 0.05). Immune perform, D-dimer, and NT-proBNP demonstrated a frequent trend with HRV throughout serious people ( < 2.05), along with severe people without enhanced HRV guidelines necessary a longer time to clear the herpes virus as well as recover ( < 3.05). HRV has been linked to the harshness of COVID-19. The particular transforming development involving HRV had been in connection with the diagnosis, implying which HRV sizes bring a non-invasive predictor regarding scientific final result.HRV was from the severity of COVID-19. The changing pattern involving HRV had been in connection with the analysis, suggesting which HRV measurements can be used any non-invasive predictor regarding specialized medical final result.Track record Prescribed regarding post-match or perhaps post-training recuperation techniques throughout young soccer gamers is often a key factor in order to boost baseball performance. Since effectiveness regarding healing methods might found interindividual variability, scientific evidence-based recuperation approaches and methods found in grownups may be certainly not appropriate for you to youthful soccer participants. For that reason, the existing systematic assessment largely targeted presenting a vital value determination along with review of the initial research articles which have examined the effectiveness of recuperation strategies in small man football people and present adequate expertise concerning the success of the healing strategies and strategies. Methodology A structured lookup ended up being performed srebp signal following Chosen Confirming Goods for Systematic Review along with Meta-Analyses (PRISMA) guidelines till November Thirty one, 2020, using the following info bottoms WOS, PubMed, Cochrane Collection, Evidence Databases (Pedrolati), Evidence Dependent Medication (EBM) Lookup assessment, EMBASE, as well as Scopus. There were no filtration utilized.

#inhibitor #small molecules #chemicals #kinase inhibitors #tyrosine kinase inhibitors #enzyme inhibitors #protein inhibitors #proteins kinase inhibitors #phosphatase inhibitors #compound library #activators #modulators #agonists #antagonists

0 notes

rohans18 · 10 months

Text

Pulmonary Embolism Market Analysis and Forecast to 2029

Global Pulmonary Embolism Market, By Symptoms (Shortness of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Others), Diagnosis (Chest X-Ray, ECG, MRI, CT Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Others), Treatment (Medications, Mechanical Devices, Surgery, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

In the consistent Pulmonary Embolism market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Pulmonary Embolism industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Pulmonary Embolism market report brings precise and exact market research information that drives business into the right direction.

Key Players

Cyanotech Corporation (U.S.)

I.D. - Parry (India) Limited (India)

BlueBioTech International GmbH (Germany)

Algatech Ltd. (Israel)

Tianjin Norland Biotech Co., Ltd. (China)

AlgaeCan Biotech Ltd. (Canada)

AstaReal AB (Sweden)

Yunnan Alphy Biotech Co., Ltd. (China)

Fenchem (China)

Piveg, Inc. (U.S.)

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-pulmonary-embolism-market

The research studies entailed in the winning Pulmonary Embolism market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Pulmonary Embolism Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

0 notes

accurizemarketresearch · 3 years

Link

The global D-dimer testing market size was valued at US$ 1.23 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2021 to 2028. A paradigm shift towards the demand for next-generation point-of-care D-dimer testing is driving the global D-dimers market.The D-dimer test is used to find out if the patient is suffering from blood clotting disorder. The clotting of blood is very important, if the blood is not clotted, it may ooze out and the patient suffers from heavy blood loss. The leftovers floating in the blood is called D-dimer, excessive clotting may lead to coagulation of D-dimers in the blood vein which can cause serious issues and can be fatal. D-dimers are widely used for the exclusion of VTE.

#D-Dimer Testing Market Global Scenario Market Size Outlook Trend and Forecast 2019 – 2028

0 notes

newsbulletin · 3 years

Text

D-dimer Testing Market Size Worth US$ 1.83 Billion by 2028

New York, NY 20 May 2021: The global D-dimer testing market is expected to reach US$ 1.83 billion by 2028 according to a new study by Polaris Market Research. The report “D-dimer Testing Market Share, Size, Trends, Industry Analysis Report, By Product (Analyzers, Reagents & Consumables); By Testing Method [Enzyme-linked Immunosorbent Assay (ELISA), Latex-enhanced Immuno-turbidimetric Assays, Fluorescence Immunoassays, Others]; By Application; By End-Use; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global D-dimer testing industry is anticipated to grow, owing to the advent of automated PoC analyzers, patient’s awareness coupled with new pathology and labs bringing down the cost of tests and more research into the synthesis of innovative aptamers. Market players are more focused on decreasing the test’s turnaround time with the highest efficacy rates.

The global market for D-dimer testing is fragmented based on the product, method, application, end-use, and region. In terms of product, the market for D-dimer testing industry is segmented into analyzers, and reagents & consumables. The method segment is further divided into enzyme-linked immunosorbent assay (ELISA), latex-enhanced immuno-turbidimetric assays, fluorescence immunoassays, and others.

The application segment of D-dimer testing industry is further divided into deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and others. The end-use market segment is further divided into hospitals, academic & research institutes, diagnostic centers, and others.

Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/d-dimer-testing-market/request-for-sample

Segment Highlights

The reagents & consumables market segment accounted for the largest revenue share of the global D-dimer testing industry in 2020 owing to the availability of readymade aptamers. The segment held over 60% of the global share in 2020.

Based on method, the ELISA market segment is projected to constitute almost half of the market in 2028. The segment holds the major share due to the introduction of automated ELISA systems in the D-dimer testing industry.

North America D-dimer testing industry accounted for the largest market revenue share in 2020. The rising cases of pulmonary embolism and deep vein thrombosis coupled with advanced clinical infrastructure boosting the usage of the concerned procedure.

Asia Pacific D-dimer testing industry is expected register higher market growth trajectory over the study period owing to the advancements in clinical research and assay systems installations particularly in the newly established government-funded hospitals.

List of Key Players

Diazyme Laboratories, Inc.

Siemens Healthineers

Thermo Fisher Scientific Inc.

Roche Ltd.

Abbott

Quidel Corporation

bioMerieux SA

HORIBA, Ltd.

Biomedica Diagnostics

Sekisui Diagnostics

Others

To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/d-dimer-testing-market/request-for-discount-pricing

Polaris Market Research has segmented the D-dimer testing market report on the basis of product, testing method, application, end-use, and region:

D-dimer Testing, Product Outlook (Revenue – USD Million, 2016 – 2028)

Analyzers

Reagents & Consumables

D-dimer Testing, Testing Method Outlook (Revenue – USD Million, 2016 – 2028)

Enzyme-linked Immunosorbent Assay (ELISA)

Latex-enhanced Immuno-turbidimetric Assays

Fluorescence Immunoassays

Others

D-dimer Testing, Application Outlook (Revenue – USD Million, 2016 – 2028)

Deep Vein Thrombosis (DVT)

Pulmonary Embolism (PE)

Disseminated Intravascular Coagulation (DIC)

Others

D-dimer Testing, End-Use Outlook (Revenue – USD Million, 2016 – 2028)

Hospitals

Academic & Research Institutes

Diagnostic Centers

Others

Have Any Query or Specific Requirement? Request for customization: https://www.polarismarketresearch.com/industry-analysis/d-dimer-testing-market/request-for-customization

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Polaris Market Research

Phone: 1–646–568–9980

Email: [email protected]

Web: http://www.polarismarketresearch.com

#D-dimer Testing market D-dimer Testing Insight D-dimer Testing Growth D-dimer Testing size D-dimer Testing share D-dimer Testing trends D-di

0 notes

cindy893 · 5 years

Text

D-dimer Testing Market: 2019 Report Overview and Forecast

Global D-dimer Testing Market report supplies an in-depth insight of industry covering all important parameters and investigation of economic dynamics is carried out. Throughout the D-dimer Testing statistical analysis, the report shows the total international economy of the market including capacity, production, production value, cost/profit, supply/demand, along with import/export.

'D-dimer Testing market covers leading regions and nations of the globe, which demonstrates a regional advancement status, for example, market size, and value details.'

Get Free Sample of this Report at: http://www.marketresearchglobe.com/request-sample/924270

Assessment of Growth Opportunities

The D-dimer Testing report gives you the capacity to determine real increase opportunities available and knows the business competence of leading players. It offers you invaluable D-dimer Testing insights to create forward-looking and sustainable growth applications for your organization. It also provides you with analytical D-dimer Testing information, operational, and industry intelligence to anticipate and address potential market barriers.

D-dimer Testing Market Report Simplifies the Leading Players:

Abbott, Beckman Coulter, Grifols, Becton Dickinson, Roche, Helena Laboratories, Sysmex, Siemens, Thermo Fisher Scientific

D-dimer Testing Market Analysis by Types:

Point-of-Care Tests

Laboratory Tests

D-dimer Testing Market Analysis by Applications:

Deep Vein Thrombosis

Pulmonary Embolism

Disseminated Intravascular Coagulation

Geographically, Global D-dimer Testing Market Report Covers the Regions:

United States, Europe, China, Japan, Southeast Asia, India, Central and South America

Grab With Discounted Price at: http://www.marketresearchglobe.com/check-discount/924270

The D-dimer Testing market report serves key methods to industries or clients to let them have awareness regarding the current global competitive status, share, and size. The report focuses on the evaluation of D-dimer Testing growth opportunities, challenges, market threats, and constraining facets.

Research Objectives of the D-dimer Testing Market Report:

To study and analyze the global D-dimer Testing intake (volume & value) by crucial regions/countries, product type, and application;

To comprehend the arrangement of D-dimer Testing market by identifying its various sub-segments;

Focuses on the vital global manufacturers, to specify, clarify and analyze the product sales amount, value, D-dimer Testing market share, contest landscape, SWOT analysis, and development plans in the next several years;

To investigate the connection to individual D-dimer Testing growth trends, prospects, and also their participation in the total market;

To discuss comprehensive D-dimer Testing information about the crucial variables affecting the growth of the market;

To project the consumption of D-dimer Testing sub-markets, concerning vital regions (along with their respective important nations);

To analyze competitive D-dimer Testing progress such as expansions, arrangements, new product launches, and acquisitions on the market;

To profile the vital D-dimer Testing players and comprehensively analyze their growth strategies;

Inquiry Before Puchasing: http://www.marketresearchglobe.com/send-an-enquiry/924270

Customization of this Report: This D-dimer Testing report could be customized to the customer's requirements. Please contact our sales professional ([email protected]), we will ensure you obtain the report which works for your needs.

#D-dimer Testing D-dimer Testing Market D-dimer Testing Market Size D-dimer Testing Market Trends D-dimer Testing Market Research Report

0 notes

drblessedsoul · 4 years

Text

Covid-19 (CoronaVirus) Guidelines

Covid Management Guidelines as of 19 Oct 2020

*Level 1. Protection ground work*

• Aspirin 75 - 100 mg + Famotidine 20mg (not if any gastric ulcers or major bleedings or haemoglobin <8)

• Crestor 5mg (under medical supervision, not if severe liver problem)

• VitD3 5000 IU softgel + GNC DHA CoQ10 every morning

• Becozinc twice daily

++++++++++ Extra Measures +++++

• Septline 1 tablet 2 times a day

• Organic (non manuka) honey every day

• Probiotic gargle and drink every night

- Start immediately for atleast 3 months

- for everyone except <21 yr old (can take honey + probiotics)

*Level 2. Post exposure prophylaxis* – e.g. When a person is completely fine but family member has any fever or suspicion of COVID

In addition to level 1 above

- Ivermectin 12mg X 2 tabs once a day for 3 days then every 3rd day till there is exposure.

- MuciNAC 600mg twice a day

- increase Septilin 2 tablet 2 times a day

- VitC 1000mg/day in 2-4 devided dose

*Level 3. Initial hint of symtoms – e.g. fever, cough, weakness etc*

In addition to level 1 & 2 above

- Cipzen forte 2 tab 2-3 times day

- Isoprinosine 2 tablet 2-3 times a day (if available)

- Book next day CBC CRP immediately

- CRP + CBC (~600 INR) every 48 hours thereafter, until completely recovered

- add IL6, D dimer on 5th day from symptom, repeat in 48hr to observe trend

*4. If CRP, IL6, D Dimer or CBC worsening, expect to develop serious COVID w oxygen requirement within 5-7 days of first symptoms*

-Monitor BP and spo2 4hrly

Cosider following under medical supervision

• Avigan 200mg (or Fabiflu) – 9 tablets two times a day on 1st day; 4 tablets 2 times a day from 2nd day onwards

• Xrelato 10mg daily

Further treatment may be needed

• Self Inj Cilaxane (300INR) daily

• Tab Dexa 3mg BD -- 24 to 48hr after starting Avigan

futher tests/ meds and possible hospitlisation based upon progress or if spO2 <95% even for a while ..

*******************

minimum 14-21 days of regular testing and vigil, even if its mild (without CRP rise).

#Besafe

1 note · View note

marketresearch-articles · 2 years

Link

0 notes

rohit0024 · 2 years

Text

D-dimer Testing Market Opportunities To Reach $1.7 Billion By 2027

D-dimer Testing Market Growth & Trends The global D-dimer testing market size is expected to reach USD 1.7 billion by 2027, expanding at a CAGR of 4.3%, according to a new report by Grand View Research, Inc. Technological advancements in D-dimer testing have resulted in the development of a wide range of products that have allowed healthcare professionals to offer suitable emergency assistance…

View On WordPress

#D-dimer Testing Market

0 notes

lupine-publishers-ctbm · 2 years

Text

Lupine Publishers |Thoughts on the Reference Range of Laboratory Tests

Lupine Publishers | Current Trends on Biotechnology & Microbiology

Abstract

This article discusses the value research data in Guan’s paper published on medRxiv, February 9, 2020. In terms of experimental data, the preprinted paper is by far the largest sample number of 2019-new coronavirus (SARS-CoV-2) infected patients. Including 552 hospitals from 31 provinces in China as of January 29, 2020, a total of 1,099 cases. Laboratory evaluations include multiple blood cell counts, blood chemistry, coagulation tests, liver and kidney function, electrolytes, C-reactive protein,

Keywords: Reference range; 2019-nCoV, SARS-CoV-2, 2019-nCoV ARD, COVID-19

Introduction

Professor Guan et al. [1] recently published an article “clinical characteristics of 2019 novel coronavirus infection in china”. It is a preprinted version of medRxiv on BMJ publishing platform. The authors of the article covered all frontline anti-epidemic frontlines including Guangzhou Institute of Respiratory Disease, Wuhan Jinyintan Hospital, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The Central Hospital of Wuhan, Huanggang Central Hospital, Department of Medicine and Therapeutics, et al. The Chinese University of Hong Kong. In this retrospective study, the authors extracted the data on 1,099 patients with laboratory-confirmed 2019-nCoV ARD (COVID-19) from 552 hospitals in 31 provinces/ provincial municipalities through January 29th, 2020. So far, it is the largest number of cases collected, the clinical characteristics of the patients with the most complete distribution, and the most comprehensive Chinese experience of SARS-CoV-2 treatment are released to the world.

In the preprinted paper, the authors found that fever occurred in only 43.8% of patients with 2019-nCoV ARD (COVID-19) but developed in 87.9% following hospitalization. Demographic data showed a median age of 47.0 years (IQR, 35.0-58.0 years). 2.09% were healthcare workers. The median incubation period was 3.0 days (range, 0 to24.0). Patients who underwent chest computed tomography on admission, 76.4% manifested as pneumonia. There are normal radiological manifestations in some infected patients. In addition, the researchers obtained a series of laboratory findings, such as 82.1% and 36.2% of patients had lymphopenia and thrombocytopenia, respectively. Overall, leukopenia was observed in 33.7% of patients. Most patients demonstrated elevated levels of C-reactive protein, rare increases in D-dimer levels, and so on. The standards used by the authors in analyzing laboratory data do not meet the standards of the People’s Republic of China’s health industry (WS/T 405-2012). We will take this article “Clinical Characteristics of New Coronavirus Infections in China 2019”as an example to explore the reference scope of laboratory test.

Methods and Results

The report delineated 1,099 patients with 2019-nCoV ARD (COVID-19) from 552 hospitals in 31 provinces/province-level municipalities. Cases were diagnosed based on the WHO interim guidance [2]. Patients were classified into severe and non-serious 2019-nCoV ARD (COVID-19) based on the guideline of the American Thoracic Society and Infectious Disease Society of America [3]. Radiologic and laboratory findings was also based on the grouping of severe and non-severe case patients. Table 1 showed lymphopenia was observed in 82.1% of patients on admission (79.3% in nonsevere cases; 95.5% in severe cases), and thrombocytopenia in 36.2% (31.6% in non-severe cases; severe cases 57.7%). Overall, leukopenia was observed in 33.7% of patients (28.1% in nonsevere cases; 61.1% in severe cases).

Hemoglobin (Hb) showed almost no significant decrease. There are significant differences of Hb level between non-serious cases and severe cases. It should be noted that only 978 of the 1099 cases provided complete blood routine test data, while the data of absolute value of lymphocytes and platelet counts were less than 978 cases. This indicating that there is no uniform requirement for the integrity of test data.

Most patients (60.7%) demonstrated elevated levels of C-reactive protein levels (56.4% in non-severe cases; 81.5% in severe cases), rare increases in alanine aminotransferase, aspartate aminotransferase, creatine kinase, and D-dimer. The authors only provided 560 cases of the D-dimer detection value, in which 46.4% patients manifest the increase tendency (43.2% in non-severe cases; 59.6% in severe cases). Severe cases had more prominent laboratory abnormalities (i.e., leukopenia, lymphopenia, thrombocytopenia, elevated C-reactive protein levels) as compared with non-severe cases (all P<0.05).

Discussion

In terms of experimental data, the preprinted paper is by far the largest sample number of 2019-new coronavirus (SARS-CoV-2) infected patients. We noticed that the author analyzed laboratory data, especially blood routine test data, and reached conclusions such as leukopenia, lymphopenia, thrombocytopenia, and elevated C-reactive protein in COVID-19 patients according to certain criteria, which is not conform to the standards of the People’s Republic of China’s health industry document WS/T405-2012.

For example, the leukopenia defined in the article is based on less than 4.0×109/L; the lymphocyte reduction is based on less than 1.5×109/L; the thrombocytopenia is based on less than 150×109/L; and the C-reactive protein level is based on be equal or greater than 10mg/L was abnormal (Table 1).

Lupinepublishers-openaccess-Agriculture

Plus-minus values are means ± SD. Lymphopenia denoted the lymphocyte count of less than 1,500 per cubic millimeter. Thrombocytopenia denoted the platelet count of less than 150,000 per cubic millimeter. PaO2:FiO2 was defined as the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen.

P values denoted the comparison between mild-moderate cases and severe cases.

As for D-dimer, the author took greater than or be equal 0.5mg/L as the standard for abnormal. However, the different hospitals in China, the difference in methods and reagents used, it is generally considered that the reference interval is less than 0.3mg/L or less than 0.5mg/L. The article uniformly took be equal or greater than 0.5mg/L as the standard for abnormal elevation. Obviously, the 552 hospitals as the participating units are unlikely to use exactly the same methods and reagents.

Lupinepublishers-openaccess-Agriculture

The China national industry standard blood routine test reference range was released in 2012, and it has been nearly eight years. The following table lists the reference range for the analysis of venous blood in the Chinese adult population for instrumental detection methods (Table 2).The preprinted article did not adopt this health industry standard, which shows that the criterion has not been accepted and recognized by Chinese clinicians. It is a very important topic whether national industry standards, especially reference ranges, are recognized by the majority of Chinese clinicians. Reference range is the basis for clinicians diagnosing diseases.

In view of the fact that the research object is Chinese, we suggest that researchers should try to adopt the domestic recommended standards instead of using the previous concepts and foreign standards. If domestic industry standards are used in this article, their statistical results and proportions may be quite different. In particular, the absolute value of lymphocytes should be significantly different, which may lead to large differences in conclusions. As we all know, the new coronavirus epidemic recently occurred in Wuhan city, Hubei Province, China has spread to other parts of China and abroad. As an acute respiratory infectious disease, the disease has been included in the Class B infectious diseases stipulated in the Law of the People’s Republic of China on the Prevention and Control of Infectious Diseases and is managed as a Class A infectious disease. The National Health Committee of the People’s Republic of China has continuously revised the “Diagnosis and Treatment Program for Pneumonia of New Coronavirus Infection”, which is currently in its fifth edition on a trial basis. The guidelines point out that the diagnosis of suspected cases of COVID-19 should be combined with a comprehensive analysis of epidemiological history and clinical manifestations.

The clinical manifestations include

1. Fever and / or respiratory symptoms

2. The imaging characteristics of pneumonia described above (abbreviated in this article)

3. The total number of white blood cells is normal or decreased in the early stage of onset, or the lymphocyte count is decreased.

Any case with epidemiological history that meets any two of the clinical manifestations can be determined as a suspected case. Once a misdiagnosis occurs due to a misjudgment of the reference value range, it is likely to cause severe unforeseen consequences.

The biochemical test results involved in the preprint version of the article also did not adopt domestic standards, and the determination of many biochemical indicators is also related to gender, which are issues that clinicians should pay attention to. If the author team includes medical laboratory experts, I believe that the aforementioned laboratory data and reference ranges, and methodological flaw may be avoided. As stated by the authors, some cases had incomplete documentation of the exposure history, symptoms and laboratory testing given the variation in the structure of electronic database among different participating site and the urgent timeline for data extraction. Some cases were diagnosed in out-patient settings where medical information was briefly documented, and incomplete laboratory testing was applied.

On the other hand, in clinical laboratory practice, we recommend that laboratory technician communicate with clinicians to scientifically explain the clinical significance and reference range of laboratory data. Only in this way, a new reference range can be adopted and applicated in the hospital. Secondly, whether it is fully adopted or partially adopted, it depends on how technicians connect closely with the clinician and perform corresponding verification. The national industry standard is only a recommended standard, not a mandatory standard. Clinicians are generally rigorous when selecting a standard for disease diagnosis. The preprint article illustrates exactly this problem. When clinicians judge the test data, they have not adopted our health industry standards as the judgment standard. It is a typical example of the disconnection between laboratory and clinical. This is a problem worthy of laboratory physician’s reflection and deep thought.

For more Current Trends on Microbiology & Biotechnology Journal please click on below link

https://lupinepublishers.com/biotechnology-microbiology/index.php

For more Lupine Publishers Please click on below link https://lupinepublishers.com/

#Lupinepublishers #Lupine Publishers LLC #lupine publishers group

0 notes

healthcare-market · 2 years

Text

Point-of-Care Coagulation Testing Devices Market Prospects and Growth Assessment

Point-of-Care Coagulation Testing Devices Market: Introduction

Transparency Market Research delivers key insights on the global point-of-care coagulation testing devices market. In terms of revenue, the global point-of-care coagulation testing devices market is projected to expand at a CAGR of ~6% during the forecast period, owing to numerous factors, regarding which, TMR offers thorough insights and forecasts in the point-of-care coagulation testing devices market report.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56190

According to TMR’s analysis of the global point-of-care coagulation testing devices market, leading players in the market focus on new products with multiple modes and features, which will be more efficient and deliver a new level of convenience and test modes. Moreover, these players focus on increasing their penetration in new regions through mergers and acquisitions, thereby increasing their share in the global point-of-care coagulation testing devices market. For instance, in April 2019, Ortho Clinical Diagnostics, in collaboration with Diazyme Laboratories, Inc. launched its D-Dimer assay, the latest offering in Ortho’s MicroTip Partnership Assay (MPA) program.

Request for Analysis of COVID19 Impact on Point-of-Care Coagulation Testing Devices Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=56190

In terms of method, the PT/INR segment held the largest share of the global point-of-care coagulation testing devices market in terms of revenue in 2018. The segment is anticipated to dominate the market from 2019 to 2027. The ever-increasing trend of point-of-care testing and self-monitoring with PT tests is expected to fuel the growth of the segment. Furthermore, the high reliability of coagulation status on PT testing is one of the factors likely to boost the growth of the segment during the forecast period.

Based on product, the technological leap from conventional testing to automation and use of lower blood volumes contribute to the growth of the instruments/analyzers segment. Increase in the demand for quicker results, rise in the trend of self- and home-monitoring, surge in POC testing, and reliable results are the major factors projected to drive the segment in the global point-of-care coagulation testing devices market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=56190

Global Point-of-Care Coagulation Testing Devices Market: Prominent Regions

North America accounted for a leading share of the global point-of-care coagulation testing devices market in terms of revenue in 2018, followed by Europe There has been a gradual rise in the demand for multiplexing diagnostic tools, and an increase in investments toward the development of these tools. Surge in the demand for more rapid and specific diagnosis to support rapid decision-making drives the global point-of-care coagulation testing devices market. Additionally, the demand for these tools in physician offices and emergency departments as standard testing tools is rising. Recent FDA approvals for point-of-care coagulation testing devices, such as Abbott’s i-STAT, indicate the increasing demand and support among both, public and private sectors, along with manufacturers’ focus on addressing this rising demand. Asia Pacific is witnessing gradual adoption of novel products, increase in healthcare expenditure, and change in dynamics in the in vitro diagnostics industry. These factors are leading to a rise in the adoption of new technologies among hospitals and diagnostic laboratories.

Buy now Point-of-Care Coagulation Testing Devices Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=56190&ltype=S

Key manufacturers in the global point-of-care coagulation testing devices market focus on collaborations in order to sustain in this competitive market space. Increase in the sales of point-of-care coagulation testing devices through e-Commerce sites and purchase of devices online have positively impacted the global point-of-care coagulation testing devices market. Easy-to-compare prices of numerous products has led to a rise in the preference for online sales.

Global Point-of-Care Coagulation Testing Devices Market: Key Players

Key players operating in the global point-of-care coagulation testing devices market include F. Hoffmann-La Roche AG, Abbott Laboratories, Siemens Healthineers, Medtronic plc, Haemonetics Corporation, HemoSonics, LLC, Micropoint Bioscience, Inc., Werfen, Sienco, Inc., and Koninklijke Philips N.V.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.co.uk/news-releases/continuous-r-amp-d-to-expand-therapeutic-use-of-platelet-rich-plasma-prp-in-regenerative-therapies-offer-profitable-opportunities-to-platelet-rich-plasma-market-players-global-market-valuation-to-reach-us-811-34-mn-by-2030-tmr-study-825481498.html

https://www.prnewswire.com/news-releases/increase-in-demand-for-new-therapies-for-effective-management-to-drive-global-menopausal-hot-flashes-treatment-market-says-tmr-301378552.html

https://www.prnewswire.com/news-releases/plant-based-vaccines-market-is-expected-to-reach-us-2-34-billion-by-2031-end-emergence-of-numerous-infectious-diseases-to-fuel-growth-of-the-market-says-tmr-301385503.html

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com

0 notes

pharmatech · 3 years

Text

Coagulation Reagents Market Will Generate New Growth Opportunities in the next 5 year

Coagulation reagents market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 4,343.42 million by 2027 from USD 2,069.76 million in 2019 growing at a CAGR of 9.70% in the above-mentioned forecast period. The increasing technological advancements have been directly impacting the growth of coagulation reagents market.

Request Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-coagulation-reagents-market

Rising incidence of cardiovascular diseases and blood disorders is expected to have a significant impact on the demands for coagulation reagents market in the forecast period of 2020 to 2027. Other impactful reason for the increased usage of coagulation reagents has been the increased innovations and advancements of technologies and rising geriatric population. On the other hand, rising reagent rental business and emerging markets will further cater ample opportunities that will lead to the growth of coagulation reagents market in the above mentioned forecast period.

Global Coagulation Reagents Market Scope and Market Size

Coagulation reagents market is segmented on the basis of test type, technology and end use. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on test type, the coagulation reagents market is segmented into APTT, d-dimer, fibrinogen, prothrombin and others.

On the basis of technology, the coagulation reagents market is segmented into mechanical, electrochemical, optical and others.

Coagulation reagents market has also been segmented based on the end use into hospitals, research institutes, diagnostic centers and others.

Request for TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-coagulation-reagents-market

Coagulation Reagents Market Country Level Analysis

Coagulation reagents market is analyzed and market size insights and trends are provided by country, test type, technology and end use as referenced above.

The countries covered in the coagulation reagents market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

Competitive Landscape and Coagulation Reagents Market Share Analysis

Coagulation reagents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to coagulation reagents market.

Inquiry Before Buy @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-coagulation-reagents-market

The major players covered in the coagulation reagents market report are Pee Emm Enterprises, Sclavo, Operon Biotech, Randox Laboratories Ltd., BIO DIAGNOSTICS, Medirox AB,Transasia Bio-Medicals, Robonik India, Sekisui Diagnostics, Haemonetics Corporation, Agappediagnostics , Rayto Life and Analytical Sciences Co. Ltd., ASPEN DIAGNOSTICS Private Limited andBeijing Steellex Scientific Instrument Co., Ltd. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

0 notes

marketresearchstrategy · 3 years

Text

Hemostasis Analyzers Market Share, Industry Growth, Trend, Drivers, Challenges, Key Companies by 2026

Increasing prevalence of cardiovascular and blood-related disorders, growing geriatric population, and increasing laboratory automation are key factors contributing to high CAGR of Hemostasis Analyzers during the forecast period.

the global Hemostasis Analyzers market was valued at USD 2,829.2 Million in 2018 and is expected to reach USD 6,304.1 million by the year 2026, at a CAGR of 10.4 percent.

The growing incidence and large economic burden of blood-related diseases and the rise in healthcare spending have resulted in the increased use of coagulation analyzers.

The increasing frequency of blood clotting disorders, coupled with increasing incidences of excessive blood loss in individuals during medical procedures are key factors boosting the growth of the global hemostasis analyzers market. Moreover, growing awareness regarding hemostasis among individuals in emerging economies, and technological advancements in hemostasis analyzers are some of the key factors propelling market growth in the industry.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2208

The report provides extensive coverage of the supply chain, key players of the industry, consumer base, company profiles, production and consumption rate, primary applications, and other relevant data. It provides an in-depth assessment of the key companies operating in the market along with their company profiles, business overview, production and manufacturing capacity, product portfolio, financial standing, global position, and business expansion plans. It also studies recent mergers and acquisitions, joint ventures, product launches, partnerships, collaborations, and agreements among other. The report also provides insights into new entrants and their strategic alliances to gain a robust footing in the market.

Key Manufacturers in the Global Hemostasis Analyzers Market:

Siemens Healthcare, Thermo Fisher Scientific, Instrumentation Laboratory Werfen Group, Sysmex Corporation, Roche Diagnostics, and Diagnostica Stago, among others

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2208

The report also provides an extensive regional segmentation to offer the readers key insights into the spread of the market over key geographical regions. It covers production and consumption patterns, import/export, supply and demand, consumer demand and behavior, key trends, and presence of key players in each region. The report also offer a country-wise analysis to impart a better understanding of the revenue growth of the market in each region.

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, France, Rest of Europe)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Product (Revenue, USD Million; Volume, Kilo Tons; 2016–2026)

Reagents

Standards, Controls, and Calibration

Automated Systems

Semi-Automated Systems

Manual

Test Type (Revenue, USD Million; Volume, Kilo Tons; 2016–2026)

Prothrombin Time

Fibrinogen

Activated partial Thromboplastin Time

Activated Clotting Time

D Dimer

Platelet Function

Anti-factor Xa

Heparin & Protamine response Test for ACT

Other Coagulation Tests

Technology Type (Revenue, USD Million; Volume, Kilo Tons; 2016–2026)

Mechanical

Optical

Electrochemical

Other Technologies

End Use (Revenue, USD Million; Volume, Kilo Tons; 2016–2026)

Diagnostic Centers

Hospitals

Research Institutes

Other end users

To know more about the report @ https://www.reportsanddata.com/report-detail/hemostasis-analyzers-market

Key Questions Addressed in the Report:

What is the market size the global Hemostasis Analyzers market is expected to reach over the forecast period? What is the expected CAGR?

What are the key segments of the market?

What are the key products and applications of the Hemostasis Analyzers market?

What factors are expected to drive and restrain market growth over the forecast period?

What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2208

Thank you for reading our report. The report can be customized based on regional segmentation and competitive landscape. Kindly get in touch with us to know more and our team will ensure the report is well suited to meet your requirements.

Browse more related reports:

Surgical Devices Market @ https://www.medgadget.com/2021/10/surgical-devices-market-growth-driven-by-increasing-need-to-treat-chronic-diseases-worldwide-reports-and-data.html

Nanomedicine Market @ https://www.medgadget.com/2021/10/nanomedicine-market-growth-driven-by-increasing-need-to-treat-chronic-and-infectious-diseases-worldwide-reports-and-data.html

BCG Vaccine Market @ https://www.medgadget.com/2021/10/bcg-vaccine-market-growth-driven-by-growing-demand-for-bacillus-calmette%e2%80%90guerin-bcg-vaccine-for-prevention-of-tuberculosis-reports-and-data.html

Bioreactors and Fermenters Market @ https://www.medgadget.com/2021/10/bioreactors-and-fermenters-market-growth-driven-by-increasing-biopharmaceutical-applications-of-bioreactors-and-fermenters-reports-and-data.html

Digital Radiography Market @ https://www.medgadget.com/2021/10/digital-radiography-market-growth-driven-by-rapid-digitization-in-the-healthcare-sector-reports-and-data.html

0 notes

rohans18 · 11 months

Text

Pulmonary Embolism Market Forecast by Current Industry Status and Growth Opportunities

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Pulmonary Embolism marketing report. The report has a lot to offer to both established and new players in the Pulmonary Embolism industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Pulmonary Embolism market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

Teva Pharmaceutical Industries Ltd.(Jerusalem)

Sanofi (France)

Pfizer Inc. (US)

GlaxoSmithKline plc (UK)

Bristol-Myers Squibb Company (U.S.)

Hikma Pharmaceuticals PLC (UK)

Johnson & Johnson Private Limited (US)

Novartis AG (Switzerland)

Boehringer Ingelheim International GmbH. (Germany)

Fresenius Kabi AG (Germany)

Bayer AG (Germany)

Eli Lilly and Company (US)

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-pulmonary-embolism-market

With the help of credible Pulmonary Embolism market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Pulmonary Embolism market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Pulmonary Embolism Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

0 notes

ford-089 · 3 years

Text

Hemostasis Diagnostics Market 2021 Industry Size, Share, In-Depth Qualitative Insights, Growth Opportunity, Regional Analysis by 2027

Hemostasis Diagnostics Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2021-2027 – Increased prevalence of blood clotting disorders and increase in technological advancements are the key drivers for Global Hemostasis Diagnostics Market.

Hemostasis Diagnostics Market is valued around USD 2228.8 Million in 2018 and expected to reach USD 3948.6 Million by 2025 with the CAGR of 8.1% over the forecast period.

Hemostasis diagnostics are those devices which help in the identification of hemostatic defects which leads to excessive bleeding. Hemostasis is a mechanism followed by the body after getting injured, it slows down the blood loss and stop the blood flow. This process is followed by three steps which include vasoconstriction, platelet plug formation and blood coagulation. Hemostasis helps in the diagnosis of actual cause of these disorders with history and helps in the treatment. So, during the study of global hemostasis diagnostics market, we have considered product type, test type and end use to analyze the market

Global hemostasis diagnostics market report is segmented on the basis of product type, test type, end use and by regional & country level. Based upon product type, global hemostasis diagnostics market is classified laboratory systems, consumables, and point-of-care testing systems. Based upon test type, global hemostasis diagnostics market is classified as prothrombin time, activated partial thromboplastin time, fibrinogen degradation products, activated clotting time, platelet aggregation test and D dimer. Based upon end user, global hemostasis diagnostics market is classified as hospital/clinics, independent diagnostic, laboratories and other002E

Get Sample Copy of This Premium Report @ https://brandessenceresearch.com/requestSample/PostId/256

The regions covered in this hemostasis diagnostics market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Hemostasis Diagnostics is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Hemostasis Diagnostics Market Reports–

Global hemostasis diagnostics market report covers prominent players like Abbott Laboratories, F. Hoffmann-La Roche Ltd., Nihon Kohden Corporation, Thermo fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, Siemens Healthineers, Alere Inc., Instrumentation Laboratory, Grifols S.A. and others.

Increase in the prevalence of blood clotting disorders and technological advancement

The commercialization and growth of global hemostasis diagnostics market over the past 25 years has been highly impactful. One of the major factors driving the growth of hemostasis diagnostics market over the forecast period is increased prevalence of blood clotting disorders such as hemophilia and others. As per Centers for Disease Control and Prevention report, Hemophilia A affects 1 in 5,000 male births and around 400 babies are born with hemophilia A each year. Moreover, increase in technological advancements for the development of advanced products for hemostasis diagnostics are also expected to support the growth of hemostasis diagnostics market over the forecast period. Furthermore, development of advanced diagnostic tools has enables the healthcare professionals to detect the blood clotting factors and provide better treatment are also expected to fuel the growth of hemostasis diagnostics market over the forecast period.

North America is Expected to Dominate the Hemostasis Diagnostics Market

North America dominates the market with highest market share over the forecast period owing to the well established healthcare facilities, high healthcare expenditure and increased awareness about hemostasis diagnostics. Europe is expected to the second largest growing region over the forecast period due to the increased awareness and increased demand of technologically advanced diagnostics. Asia Pacific is expected to be the third largest and fastest growing region of hemostasis market over the forecast period due to the increased awareness among people, increase in product launches and increase in per capita income are expected to promote the growth of hemostasis diagnostics market over the forecast period. Latin America, Middle East and Africa are expected to develop considerably over the forecast period.

Key Benefits for Global Hemostasis Diagnostics Market Reports –

Global market report covers in depth historical and forecast analysis.

Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global market report helps to identify opportunities in market place.

Global market report covers extensive analysis of emerging trends and competitive landscape.

Request for Methodology Report @ https://brandessenceresearch.com/requestMethodology/PostId/256

Hemostasis Diagnostics Market Segmentation –

By Product Type

Laboratory Systems, Consumables, Point-of-Care Testing Systems

By Test Type

Prothrombin Time, Activated Partial Thromboplastin Time, Fibrinogen Degradation Products, Activated Clotting Time, Platelet Aggregation Test, D Dimer

By End User

Hospital/Clinics, Independent Diagnostic, Laboratories, Other

By Region: North America (US., Canada), Europe (UK., France, Germany, Italy), Asia Pacific (China, Japan, India, Southeast Asia), Latin America (Brazil, Mexico), Middle East and Africa (GCC, Africa, Rest of Middle East and Africa)

Get Full Report : https://brandessenceresearch.com/healthcare/hemostasis-diagnostics-market

0 notes

96thdayofrage · 3 years

Text

The “Killer Vaccine” Worldwide. 7.9 Billion People

The Covid-19 Vaccine should be Halted and Discontinued Immediately Worldwide

“Killer Virus” or “Killer Vaccine”?

The first question which stands out is: Do We Need a Vaccine?

The answer is NO! There is no scientific basis whatsoever which justifies the gene-edited vaccine as a means to saving lives and protecting people’s health Worldwide.

The alleged “scientific justification” for the vaccination program relies on the three simple and misleading “phrases” or “labels” which are totally invalid:

SARS-COV-2 is a “killer virus”

There is a rising Worldwide trend of covid-19 infection,

People are dying as a result of the covid-19 infection.

1. SARS-CoV-2 is “a killer virus”.

That’s the cornerstone of the 24/7 fear and media disinformation campaign upheld by persistent statements by politicians and national health authorities.

Both the peer-reviewed as well the WHO, CDC “official” definitions of SARS-CoV-2 say exactly the opposite. Their definitions of SARS-2 repeal their own lies. (For details see Appendix)

2. There is a Rising Worldwide Trend of Covid-19 infection.

This alleged trend is said to be corroborated by a rapidly increasing number of covid positive cases.

The methodology used to generate these figures is dependent upon the WHO sponsored Real Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) test, the estimates of which are tabulated Worldwide by the national health authorities.

While the estimates of the rRT-PCR have been questioned from the very outset, it is now confirmed by the WHO in a January 20, 2021 advisory that the rRT-PCR test adopted as a means to detecting the SARS-COV-2 virus cases is TOTALLY invalid. (This pertains to Covid positive data tabulated since late January 2020). (See Appendix)

3. People are Dying as a Result of the Covid-19 Infection.

We are told that there is a rising trend of Covid-19 mortality. Namely deaths which are allegedly the result of the SARS-2 viral infection.

There is ample evidence that these Covid-19 related probable causes of death and the underlying data on Covid-19 mortality are manipulated by the national health authorities. Tests, autopsies and postmortems are not conducted. The mortality statistics pertaining to Covid-19 are TOTALLY invalid. (see Appendix which focusses on the US covid related mortality data )

In summary,

1. there is no killer virus,

2. the measurement of covid positive cases is invalid,

3. the Covid-19 mortality data are manipulated.

All of these statements are amply documented. For details see Appendix to this article below.

I should mention that the so-called “emergency use” clause to justify an experimental and unapproved vaccine is also invalid. Why? Because the emergency use criterion relies on erroneous estimates of the rRT-PCR covid positive cases (fake) and Covid-19 related mortality data, both of which are invalid. (See Appendix)

The Vaccine. Hidden Agenda?

The vaccine does not save lives nor does it contain the pandemic, because there is no pandemic. It’s a money-making operation for Big Pharma in the hundreds of billions of dollars (see data below).

Moreover, it’s not a one time vaccine jab. Several doses are contemplated. It is slated to extend over a period of at least two years.

It is applied Worldwide without exceptions. Not a single country with the exception of Burundi, Tanzania and Haiti had the courage to refuse the “killer vaccine”.

While there is no reliable evidence, it is worth noting that the presidents of Tanzania and Burundi died under mysterious circumstances.

Haiti was until recently the only country in the Western Hemisphere which refused categorically to implementing the mRNA vaccine. In a bitter irony, immediately following president Jovenel Moise’s assassination (July 7, 2021), president Joe Biden promptly sent half a million vaccine doses (and more to come) (courtesy of Uncle Sam) which were delivered by COVAX to Port au Prince six days later on July 14.

This first shipment to Haiti was part of a US Aid program consisting of 500 million doses of the “killer vaccine” which is slated to be sent to a large number of developing countries (For further details see below).

Mortality and Morbidity: While there is no “Killer Virus”, there is a “Killer Vaccine”.

The evidence is overwhelming. At the time of writing, almost 20,000 Covid vaccine deaths have been recorded in the European Union (July 17, 2021). In the US the number of registered vaccine related deaths is of the order of 12,000 (July 9, 2021).

According to the EudraVigilance database (July 17, 2021) there were 18,928 deaths and 1,823,219 injuries reported following injections of four experimental COVID-19 shots.

COVID-19 MRNA VACCINE MODERNA (CX-024414)

COVID-19 MRNA VACCINE PFIZER-BIONTECH

COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)

COVID-19 VACCINE JANSSEN (AD26.COV2.S)

From the total of injuries recorded in the EU, “half of them (904,609) are serious injuries“. According to EuroViligance (quoted by by Brian Shilhavy):

“Seriousness … can be classified as ‘serious’ if it corresponds to a medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.”

These are official statistics based on a formal process of registration of deaths and “adverse effects”. The actual number of deaths and injuries triggered by the mRNA vaccine are much higher. Less than ten percent of the victims or families of the deceased will go through the tedious process of reporting vaccine related deaths and injuries to the national health authorities.

According to the latest “official” figures for the EU, Britain and the US (combined), there are 31,389 Covid-19 vaccine related deaths and almost 5 million injuries.

EU/EEA/Switzerland to 17 July 2021 – 18,928 Covid-19 injection related deaths and over 1.8 million injuries, per EudraVigilance Database.

UK to 7 July 2021 -1,470 Covid-19 injection related deaths and over 1 million injuries, per MHRA Yellow Card Scheme.

USA to 9 July 2021 – 10,991 Covid-19 injection related deaths and over 2 million injuries, per VAERS database.

TOTAL for EU/UK/USA – 31,389 Covid-19 injection related deaths and almost 5 million injuries reported so far in July 2021.

Hidden Injuries: The Microscopic Blood Clots

The persons vaccinated will not be immediately aware of the injuries incurred. The latter in most cases are not discernible, nor are they recorded. While “Big Blood Clots” resulting from the vaccine are revealed and reported by those vaccinated, an important study by Canada’s Dr. Charles Hoffe, suggests (yet to be fully confirmed) that the mRNA vaccine generates “microscopic blood clots”.

“The blood clots we hear about which the media claim are very rare are the big blood clots which are the ones that cause strokes and show up on CT scans, MRI, etc.

The clots I’m talking about are microscopic and too small to find on any scan. They can thus only be detected using the D-dimer test.”

“These people have no idea they are even having these microscopic blood clots. The most alarming part of this is that there are some parts of the body like the brain, spinal cord, heart and lungs which cannot re-generate. When those tissues are damaged by blood clots they are permanently damaged.

“These shots are causing huge damage and the worst is yet to come.”

Big Pharma. Pfizer’s Near Global Monopoly

Hundreds of billions of dollars are at stake. This is the largest and most expensive vaccine project in World history which is slated to be financed by tax dollars Worldwide, putting an obvious strain on the public debt of numerous countries.

The vaccine program is accompanied by a “timeline” consisting of recurrent mRNA inoculations over “the next two years and beyond”. As documented above, it will have devastating impacts on mortality and morbidity Worldwide.

What is at stake is a multi-billion dollar Big Money operation for Big Pharma with Pfizer in the lead.

Pfizer-BioNTech (allied with Moderna Inc) is in the process of consolidating its Worldwide (near monopoly) position by pushing out its major competitors including AstraZenaka and Johnson and Johnson (J & J).

Pfizer has been pressuring politicians to endorse their mRNA vaccine. It’s political lobbying is also directed against its Big Pharma competitors. According to Bureau Investigates report:

One official who was present in the unnamed country’s negotiations described Pfizer’s demands as “high-level bullying” and said the government felt like it was being “held to ransom” in order to access life-saving vaccines.

Ironically, in the EU, the reported deaths and injuries were used by the European Commission to cancel the renewal of the contract with AstraZeneka, despite the fact that there were substantially more deaths and injuries associated with the Pfizer-BioNTech vaccine.

In April 2021, the EU Commission confirmed that it would “end AstraZeneca and J&J vaccine contracts at expiry”. “The Pfizer shot will take precedence”. Never mind your followup dose with AstraZeneka, the health authorities have instructed people to get their second or third jab with Pfizer or Moderna (thereby visibly violating medical norms).

Having sidelined its competitors, Pfizer-BioNTech has jacked up the price of the vaccine vial. Pfizer has literally cornered both the EU and US markets. A near global vaccine monopoly is in the making.

The European Union

In mid-April 2021 the President of the European Commission confirmed that Brussels is in process of negotiating a contract with Pfizer for the production of 1.8 billion mRNA vaccine doses, which represents 23 percent of the World’s population.

That’s exactly four times the population of the 27 member states of the European Union (448 Million, 2021 data), which confirms that several followup doses of the “killer vaccine” are envisaged, despite the trend in mortality and morbidity which the governments and the media are attempting to suppress as part of a hideous disinformation campaign.

Pfizer and the US Market

A similar pattern is occurring in the US and Canada. In July 2020, Pfizer signed a $1.95 billion contract with the U.S. government for 100 million doses. And then in December 2020 another 100 million doses were delivered.

In Canada, another 35 million doses of Pfizer and Moderna vaccine vials are slated to be delivered.

And now July 2021 the Biden administration has ordered 200 million more doses of the Pfizer vaccine. “for children’s shots and possible boosters”

But that’s not all: in early June 2021, Biden ordered 500 million Pfizer-BionTech doses of the “killer virus” to be sent as “US Aid” to developing countries (courtesy of Uncle Sam).

In most Western countries including the US and Canada, the retail price of the vaccine is “Free”.

In the US, a total of 900 million doses of Pfizer-BionTech vaccine vials is Big Money for Big Pharma: Massive profits for Pfizer, all of which are slated to be financed by tax revenues coupled with a dramatic expansion of the US public debt.

In the first quarter of 2021 (January through March 2021), the gross revenues accruing to Pfizer and Moderna were as follows:

#1. Pfizer-BioNTech COVID-19 vaccine. U.S. sales were $2.038 billion; global sales were $5.833 billion.

#2. Moderna COVID-19 vaccine. U.S. sales, $1.358 billion; global sales, $1.733 billion.

Recently announced (23 July 2021), Pfizer has jacked up the price of its vaccine vial from $19.50 to $28.00.

Multiply $28.00 by three vaccine doses per person for a World population of 7.9 billion, What do you get?

This is not an estimate, it’s an “order of magnitude”: 663.6 billion dollars ($28.00 x 3 x 7.9 billion = $663.6 billion).

It is all for a good cause: save lives?

We are talking about a multi-billion dollar operation at tax payers expense, which has resulted in a pattern of vaccine related deaths and injuries. And the governments are fully aware of what is happening.

Pfizer’s Criminal Record

Is Pfizer “a reliable partner” as claimed by the EU Commission President van der Leyen?

A global vaccine monopoly is unfolding controlled by a company which has a criminal record (2009) with the US Department of Justice.

It was not the routine civil class action law suit waged against the pharmaceutical industry. It was a criminal indictment for “fraudulent marketing”. While there were no arrests, Pfizer was so to speak “Put on Parole” under a US DOJ indictment.

In a historic US Department of Justice decision in September 2009, Pfizer Inc. pleaded guilty to criminal charges. It was “The Largest Health Care Fraud Settlement” in the History of the U.S. Department of Justice.

Pfizer to Acquire A Near Monopoly of the Global Covid Vaccine Market

And now among all major Big Pharma actors, it’s a company with a criminal record which has established a de facto near monopoly at a World Level.

Can we trust a Big Pharma vaccine conglomerate which pleaded guilty to criminal charges by the US Department of Justice (DoJ) including “fraudulent marketing” and “felony violation of the Food, Drug and Cosmetic Act”?

‘Fraudulent marketing” in the case of the Pfizer-BioNTech’s “killer vaccine” is a gross understatement. What is Value of Human Life? It does not have a monetary value.

Can we trust the politicians in high office who granted these multibillion Euro/dollar contracts to Pfizer, which are funded by tax revenues.

Is this a “mistake” on the part of the national health authorities? The experimental mRNA “vaccine” has resulted in an upward trend in mortality and morbidity Worldwide. Meanwhile, Big Pharma profits are in the hundreds of billions.

And governments, acting on behalf of Big Pharma are pressuring people to get vaccinated to no avail imposing penalties to those who refuse.

National health authorities claim that the Covid-19 “vaccine” will save lives. That’s a lie.

Do we Know What’s inside the Pfizer Vaccine Vial?

The causes of vaccine related deaths and injuries have not been addressed by the health authorities.

What is inside the vaccine vial? National health authorities have not made public the results of their lab exams. It is unclear as to whether those lab exams of the vaccine vials have been conducted.

Below is a review of the analysis and laboratory research conducted by the independent Quinta Columna Spanish team.

Graphene Oxide Nano-particules

According to lab exams conducted by the Spanish Quinta Columna research team, graphene oxide nano-particles have been detected in the vial of the Pfizer mRNA vaccine.

The results of their research (analysis by electron microscopy and spectroscopy) are far-reaching. Graphene oxide is a toxin which triggers thrombi and blood coagulation. It also has an impact on the immune system. Graphene oxide accumulated in the lungs can have devastating impacts.

0 notes